Business Context and Reporting Period
Company: Organogenesis Holdings Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 8, 2024
Reporting Period: Fiscal Second Quarter ended June 30, 2024
This filing serves as a notification that the Company announced its financial results for the second quarter of 2024 via a press release. The press release is included as Exhibit 99.1 and is furnished, not filed, for purposes of Section 18 of the Exchange Act.
Key Financial Metrics
The provided text is a cover sheet and does not contain specific financial data. The filing explicitly states that the results are detailed in the attached press release (Exhibit 99.1), which is not included in the input text. Therefore, the following metrics are not available in this document:
- Revenue
- Profit/Loss
- Cash Flow
- Margins
- Debt and Liquidity
Note: The filing text does not provide a clear value for any financial metric.
Material Changes
No material changes versus the prior comparable period are described in the text of this Form 8-K. The document only references the announcement of results without detailing the specific variances or trends.
Guidance, Outlook, and Risks
The text does not contain management commentary, forward-looking guidance, risk factors, or details on contingencies and unusual items. These elements, if present, are contained within the referenced press release (Exhibit 99.1) which is not part of the provided input.
Investor Verification Checklist
- Review the attached press release (Exhibit 99.1) for actual Q2 2024 financial figures.
- Verify the specific revenue and net income/loss numbers for the quarter ended June 30, 2024.
- Check for any updated full-year guidance or operational outlook provided in the press release.
- Confirm the status of the company's liquidity and cash position as reported in the full earnings release.